诺格白介素α-因奇西普(Nogapendekin alfa inbakicept-pmln) - 药物靶点：IL-2Rβγ_在研适应症：转移性非小细胞肺癌，原位癌，非肌层浸润性膀胱尿路上皮癌_专利_临床

概要

基本信息

药物类型

Fc融合蛋白

别名

IL-15N72D:IL-15RαSu/Fc fusion protein complex、Inbakicept、Nogapendekin alfa inbakicept

+ [6]

靶点

IL-2Rβγ

作用方式

激动剂、刺激剂

作用机制

IL-2Rβγ激动剂(白细胞介素-2受体βγ亚基复合物激动剂)、免疫刺激剂

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [11]

在研适应症

转移性非小细胞肺癌原位癌非肌层浸润性膀胱尿路上皮癌+ [33]

非在研适应症

前列腺腺癌晚期非小细胞肺癌晚期恶性实体瘤+ [26]

原研机构

Altor BioScience Corp.

在研机构

ImmunityBio, Inc.

深圳市北科生物科技有限公司

Serum Life Science Europe GmbH

+ [1]

非在研机构-

权益机构

Altor BioScience Corp.

Cigalah GroupModern Pharmaceutical Co.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2024-04-22),

非肌层浸润性膀胱肿瘤

最高研发阶段(中国)临床3期

特殊审评快速通道 (美国)、加速批准 (沙特阿拉伯)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 14770950

关联

96

项与诺格白介素α-因奇西普相关的临床试验

NCT07217496

/ Not yet recruiting临床1期

Open-Label, Single-Arm, Phase 1b Clinical Trial of NAI Plus Pembrolizumab With Short Course of Enfortumab Vedotin in Treatment-Naïve Participants With Metastatic Urothelial Carcinoma

This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic).

开始日期2026-12-01

申办/合作机构

ImmunityBio, Inc.

NCT07756593

/ Not yet recruiting临床1期IIT

A Phase Ib Study Evaluating the Safety and Tolerability of Sipuleucel-T (Sip-T) in Combination With N-803 in Patients With Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

This phase Ib single-center open-label de-escalation study uses a modified 3+3 design to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of standard of care Sip-T and N-803 in patients with metastatic androgen pathway modulation resistant (mAPMR) prostate cancer. Patients will receive treatment for up to 8 weeks.

开始日期2026-11-30

申办/合作机构

Washington University School of Medicine

[+2]

NCT07574541

/ Not yet recruiting临床2期IIT

Phase II Trial of a Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Background:
Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring. However, 35% of men with this cancer will need treatment within 5 years because of tumor growth. Researchers want to know if a new vaccine that targets 3 anti-cancer proteins (TriAdeno) plus a drug (N-803) approved for bladder cancer can help stop prostate tumors from growing.
Objective:
To test TriAdeno and N-803 in people with early-stage prostate cancer.
Eligibility:
People aged 18 years and older with early-stage low- or medium-risk prostate cancer.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have a test of their heart function. They will have an imaging scan. They may have a rectal exam.
TriAdeno is injected under the skin of the upper thigh; N-803 is injected under the skin of the abdomen. Participants will be treated in up to four 21-day cycles. They will get both injections on the first day of each cycle.
Participants may opt to complete a memory aid: They may record all of their symptoms for 7 days after each injection. They may also complete a questionnaire about their prostate symptoms.
Blood tests, imaging scans, and other tests will be repeated during the study.
A tissue sample (biopsy) of the tumor will be collected during or after cycle 2; a second biopsy may be taken about 1 year later.
Participants will have follow-up phone calls for 5 years....

开始日期2026-11-02

申办/合作机构

National Cancer Institute

100 项与诺格白介素α-因奇西普相关的临床结果

登录后查看更多信息

100 项与诺格白介素α-因奇西普相关的转化医学

登录后查看更多信息

100 项与诺格白介素α-因奇西普相关的专利（医药）

登录后查看更多信息

410

项与诺格白介素α-因奇西普相关的文献（医药）

2026-12-31·OncoImmunology

IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy

Review

作者: Goldman, Corey Keith

Durable antitumor immunity requires innate activation, antigen presentation, lymphocyte priming, trafficking, and effector function. In immunologically cold tumors, deficient dendritic-cell and natural killer (NK)-cell activation limits the transition from tumor-antigen recognition to CD8 T-cell immunity. Interleukin-15 (IL-15) is a member of the common gamma-chain cytokine family with a distinctive receptor-delivery system at this innate-adaptive interface. In native trans-presentation, IL-15 is stabilized by IL-15 receptor alpha (IL-15Rα) on an antigen-presenting cell and presented to CD122/CD132 on an apposed NK or memory CD8 T cell. This contact-dependent arrangement supports NK-cell homeostasis, memory CD8 T-cell maintenance, and spatially restricted signaling while avoiding the CD25-dependent regulatory T-cell preference of IL-2. IL-12, IL-15, and IL-18 can generate cytokine-induced memory-like NK cells with enhanced recall. These programs are constrained by intrinsic CISH feedback and by tumor-associated TGF-β, PD-L1, TIGIT, adenosine, and other suppressive pathways. Pharmacologic IL-15 receptor agonizts such as N-803 reproduce selected receptor-binding features of trans-presentation but do not reproduce its native source-cell, contact, or spatial restrictions. The durable activity of intravesical N-803 plus bacillus Calmette-Guérin in BCG-unresponsive non-muscle-invasive bladder cancer establishes clinical relevance in a localized combination setting, whereas systemic solid-tumor studies have shown pharmacodynamic lymphocyte expansion with more limited or variable clinical activity. This narrative review synthesizes IL-15 receptor biology, innate and adaptive effector programs, counter-regulation, and clinical translation. It presents the 'innate bootstrap' as a mechanistic hypothesis: appropriately timed IL-15-axis engagement may strengthen an impaired innate-to-adaptive handoff, with efficacy determined by route, tissue context, partner therapy, exposure schedule, and patient selection.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy

Article

作者: Ye, Dongni ; Yang, Min ; Chai, Xinglei ; Moradi, Ashton ; Zhao, Angela ; Lotan, Yair

AIMS:

To estimate the budget impact of adopting nadofaragene firadenovec for the treatment of adults with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors (CIS ± Ta/T1) from a US third-party payer's perspective.

METHODS:

A budget impact model was developed to compare total healthcare costs under two scenarios: (1) with nadofaragene firadenovec included in the treatment mix, and (2) without it. The model simulated a hypothetical US health plan covering one million members over a 3-year time horizon. Costs assessed included drug acquisition and administration, surveillance and disease management, cystectomy, and treatment-related adverse events (AEs). Base-case inputs were informed by trial data, published literature, and real-world evidence. Scenario analyses explored alternative population definitions, epidemiology and clinical inputs; one-way sensitivity analyses tested parameter uncertainty.

RESULTS:

In the base-case, the estimated per-member-per-month (PMPM) budget impact of adopting nadofaragene firadenovec ranged from $0.0010 in Year 1 to $0.0084 in Year 3. Increased drug and administration costs were partially offset by cost savings from reduced disease progression, fewer cystectomies, and lower AE rates. Scenario analyses demonstrated that even examining a broader population including papillary disease-only patients, the budget impact remained modest ($0.0064-$0.0548 PMPM from Years 1-3). Sensitivity analyses confirmed that results were most influenced by uptake rate, drug cost, and target population size.

LIMITATIONS:

Key limitations include reliance on projected market shares for nadofaragene firadenovec, omission of recently approved treatments (nogapendekin alfa inbakicept-pmln and TAR-200) due to the lack of publicly available market share data, and assumptions to derive clinical outcomes for certain treatments due to lack of reported data.

CONCLUSIONS:

Despite its higher acquisition cost, the inclusion of nadofaragene firadenovec resulted in a minimal budget impact as bladder-sparing option for patients with BCG-unresponsive NMIBC with CIS ± Ta/T1.

2026-11-01·EPIDEMIOLOGY

Vaccine Efficacy Against Naturally Asymptomatic Infections

Article

作者: Lipsitch, Marc ; Benkeser, David ; Rogawski McQuade, Elizabeth T. ; Dean, Natalie ; Nabi, Razieh ; Codi, Allison

The naive approach to estimating the effects of a vaccine on asymptomatic infections, which compares the risk of asymptomatic infection among vaccinated and unvaccinated individuals, can be misleading because it comprises two effects: the vaccine preventing asymptomatic infections and the vaccine converting symptomatic to asymptomatic infections. When the latter effect is strong, vaccines can appear harmful with respect to asymptomatic infections. Using a causal principal stratification framework, we formalize an estimand, vaccine efficacy against naturally asymptomatic infection (VE NAI ), that describes the efficacy of a vaccine in preventing asymptomatic infections among individuals who would naturally (i.e., in the absence of vaccine) be expected to be asymptomatic. This estimand excludes vaccine effects that convert symptomatic cases to asymptomatic infections, and we demonstrate how this makes it a more natural analogue of the usual vaccine efficacy estimands against infection and symptomatic disease. We describe the assumptions under which this estimand can be identified and estimated from randomized and observational studies. We further identify and estimate bounds that do not require cross-world independence assumptions and characterize sensitivity analyses around the main assumption needed for identification. Finally, we apply these methods to a randomized trial of the coronavirus disease 2019 mRNA-1273 vaccine. In this trial, VE NAI was higher than standard estimates of efficacy against asymptomatic infections and was similar in magnitude to efficacy against any infection. Reporting VE NAI in vaccine trials in addition to other vaccine effects would improve interpretability and could broaden understanding of vaccine impact on transmission, providing insights into immunological mechanisms.

461

项与诺格白介素α-因奇西普相关的新闻（医药）

2026-10-27

·Alien药说

医药行业日报-三季报里的"兑现"，与ESMO最后的注脚

2026年10月27日 · 医药行业24小时观察 10月26日晚到27日晨，是A股三季报最密集的窗口。截至10月26日18时，医药生物板块已有129家公司披露三季报，超四成企业同比增长。数字背后的共同线索很清楚：过去两年签下的海外授权，正在变成利润表上的真金白银；CXO的订单簿，也在同步变厚。同一天，马德里ESMO年会临近收官，第四批LBA摘要全文公开。一、药明康德：单季利润跑赢收入，全年指引再上调 10月26日晚，药明康德披露三季报：第三季度营业收入166.40亿元，同比增长38.01%；归母净利润83.18亿元，同比增长136.67%。前三季度营业收入455.37亿元，同比增长38.59%，其中持续经营业务收入同比增长46.3%；归母净利润193.98亿元，同比增长60.64%。比增速更值得看的是两处"前瞻指标"：截至9月末，持续经营业务在手订单767.4亿元，同比增长36.4%；公司同时把2026年全年收入指引从585亿—605亿元上调至610亿—619亿元。公告解释是，CRDMO模式下后期与商业化项目占比提升、早期业务量价齐升带来毛利改善，叠加精益运营的规模效应。利润增速显著快于收入，具体结构仍需完整报表拆解，但订单与指引同向抬升，至少说明景气度没有停在"预期"层面。诺诚健华则给出Biotech的另一种样本：前三季度总营收20.99亿元，同比增长88.21%，其中药品销售收入14.49亿元，同比增长41.47%；归母净利润6.56亿元，实现扭亏为盈，扣非净利润5.86亿元；经营活动现金流净额2.20亿元，由负转正。研发投入7.85亿元，占营收37.40%。公告提及与礼来的战略合作——BD不再只是"补血"，开始与产品销售构成双引擎。同一晚的其他数字则喜忧参半。翰宇药业第三季度净利润2亿元，同比增长369.76%。智飞生物第三季度营收25.15亿元、同比下降7.40%，净利润1.25亿元、同比增长117.36%，但前三季度仍亏损6.83亿元——疫苗端的修复是真的，持续性还要再看两个季度。二、SANOVO：把"全口服一线"的证据链补齐 10月26日，ESMO第四批LBA摘要全文公开，其中最受关注的是赛沃替尼联合奥希替尼一线治疗非小细胞肺癌的III期SANOVO研究。这是一项盲法、随机对照III期试验，入组326例既往未治疗、伴EGFR突变（19外显子缺失或L858R）且MET过表达的局部晚期或转移性NSCLC患者，对比安慰剂联合奥希替尼。截至2026年7月31日，在MET IHC 3+亚组（n=98）中，联合组中位无进展生存期24.8个月，对照组11.1个月（HR=0.45，P<0.0001）；ITT人群中位PFS为24.9个月对13.8个月（HR=0.56）。更关键的是总生存：中位随访38.7个月时，联合组中位OS 44.5个月，对照组34.9个月（HR=0.48）。代价是安全性。两组中位治疗暴露时间分别为22.1个月和12.9个月，因不良事件停药比例14.8%对4.3%。这也解释了为什么赛沃替尼的临床定位一直在"精选人群"上做文章——MET IHC 3+的获益幅度明显大于整体人群。 SANOVO与全球III期SAFFRON、中国III期SACHI连成一条线：从后线到一线，赛沃替尼+奥希替尼这个全口服组合正在把"MET"从一个伴随诊断标签，做成一个可复制的治疗策略。赛沃替尼由和黄医药主导中国开发、阿斯利康负责海外商业化，2011年至今的合作已进入收获期。同日，泽璟制药公告其在ESMO发布三个项目：PD-1/TIGIT双抗ZG005、DLL3×CD3三抗ZG006及ZGGS34。其中ZG005的II期扩展阶段已按1:1随机入组55例晚期宫颈癌患者。三、研发侧的三条"小而实"的进展中国生物制药双靶点进突破性治疗。10月27日早间，中国生物制药在港交所公告，附属公司正大天晴自主研发的1类新药TQ-A3334（Toll样受体7激动剂）与TQA3605（核心蛋白变构调节剂）同日被CDE纳入突破性治疗药物程序。两者指向慢乙肝治疗中两个最难啃的缺口：功能性治愈与低病毒血症。核苷类药物的"抑制"路径已到天花板，免疫激活（TLR7）与联合方案成为下一个战场。恒瑞把IL-15带进膀胱癌。10月27日公告，子公司苏州盛迪亚、上海盛迪、上海恒瑞收到NMPA核准签发的临床试验批准通知书，同意SHR-2005注射液开展联合注射用SHR-1501±阿得贝利单抗±BCG用于膀胱癌的临床试验。SHR-1501是IL-15融合蛋白，国内尚无同靶点产品获批，海外同类Anktiva已在美国上市，2025年全球销售额约1.13亿美元。众生药业给"流感药"扩边界。控股子公司众生睿创收到NMPA通知，同意昂拉地韦片开展"治疗高并发症风险甲型流感"III期临床，入组12岁及以上青少年和成人。昂拉地韦是全球首款流感RNA聚合酶PB2抑制剂，2025年5月已获批上市，此次是把适应症从"健康人群"推向"高风险人群"，同时其青少年补充申请、颗粒剂上市申请均在审。另外，白云山公告子公司王老吉药业的克感利咽口服液已启动治疗小儿急性上呼吸道感染的II期临床。观察：从"讲故事"到"交作业" 把这几条放在一起看，三季报的关键词是"兑现"——BD首付款、里程碑款进入利润表，CDMO在手订单转化为收入，共同支撑板块贝塔。但分化同样明显：同样靠BD，海思科预计前三季净利增长297%—321%，信诺维却因款项确认节奏不同预亏3.49亿—3.86亿元。授权收入的会计确认天然波动，"一次性"与"可持续"必须分开看。ESMO这边，中国资产的厚度已不需靠数量证明，接下来比的是能否在III期里赢下OS。SANOVO的44.5个月很漂亮，14.8%的停药率同样真实。（本文数据来自各公司公告及公开披露，财报数据以正式报告为准；不构成投资建议。）

2026-10-26

·搜狐新闻

证券代码：600276 证券简称：恒瑞医药公告编号：临2026-160

来源：中国证券报-中证网本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。近日，江苏恒瑞医药股份有限公司（以下简称“公司”）子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司、上海恒瑞医药有限公司收到国家药品监督管理局（以下简称“国家药监局”）核准签发关于SHR-2005注射液、注射用SHR-1501、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。现将相关情况公告如下：一、药品的基本情况 ■ 二、药品的其他情况 SHR-2005注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗膀胱癌。经查询，目前国内外尚无同类药上市。截至目前，SHR-2005注射液相关项目累计研发投入约为5,660万元（未经审计）。 SHR-1501为公司自主研发并具有知识产权的白细胞介素-15（IL-15）融合蛋白，可以刺激体内T细胞、B细胞和NK细胞增殖，发挥抗肿瘤作用。目前国外同类产品Nogapendekin Alfa Inbakicept（商品名：Anktiva）已于美国获批上市，国内未有同靶点产品获批上市。经查询EvaluatePharma数据库，2025年该产品全球销售额合计约为1.13亿美元。截至目前，注射用SHR-1501相关项目累计研发投入约12,950万元（未经审计）。阿得贝利单抗注射液是公司自主研发的人源化抗PD-L1单克隆抗体，能通过特异性结合PD-L1分子从而阻断导致肿瘤免疫耐受的PD-1/PD-L1通路，重新激活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝利单抗注射液已获批两项适应症，分别为：与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗；联合含铂化疗作为新辅助治疗，术后继续以本品作为单药辅助治疗，用于治疗可手术切除的Ⅱ、ⅢA和ⅢB期且无已知表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)重排的成人非小细胞肺癌(NSCLC)患者。国外有同类产品Atezolizumab（商品名：Tecentriq）、Avelumab(商品名：Bavencio)和Durvalumab（商品名：Imfinzi）于美国获批上市销售，其中Atezolizumab和Durvalumab已在中国获批上市。国内另有多款同类产品获批上市。经查询，2025年Atezolizumab、Avelumab和Durvalumab全球销售额合计约为110.54亿美元。截至目前，阿得贝利单抗注射液相关项目累计研发投入约137,030万元（未经审计）。三、风险提示根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。药品从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。公司将按国家有关规定积极推进上述研发项目，并及时对项目后续进展情况履行信息披露义务。特此公告。江苏恒瑞医药股份有限公司董事会 2026年10月26日返回搜狐，查看更多

2026-10-26

·同花顺

恒瑞医药：SHR-2005注射液、注射用SHR-1501、阿得贝利单抗注射液获得药物临床试验批准通知书

恒瑞医药（HK1276）(01276)发布公告，近日，江苏恒瑞医药（HK1276）股份有限公司(以下简称“公司”)子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司、上海恒瑞医药（HK1276）有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-2005注射液、注射用SHR-1501、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。 SHR-2005注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗膀胱癌。经查询，目前国内外尚无同类药上市。截至目前，SHR-2005注射液相关项目累计研发投入约为5660万元(未经审计)。 SHR-1501为公司自主研发并具有知识产权的白细胞介素-15(IL-15)融合蛋白，可以刺激体内T细胞、B细胞和NK细胞增殖，发挥抗肿瘤作用。目前国外同类产品Nogapendekin Alfa Inbakicept(商品名：Anktiva)已于美国获批上市，国内未有同靶点产品获批上市。经查询EvaluatePharma数据库，2025年该产品全球销售额合计约为1.13亿美元。截至目前，注射用SHR-1501相关项目累计研发投入约1.3亿元(未经审计)。阿得贝利单抗注射液是公司自主研发的人源化抗PD-L1单克隆抗体，能通过特异性结合PD-L1分子从而阻断导致肿瘤免疫耐受的PD-1/PD-L1通路，重新激活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝利单抗注射液已获批两项适应症，分别为：与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗;联合含铂化疗作为新辅助治疗，术后继续以本品作为单药辅助治疗，用于治疗可手术切除的Ⅱ、ⅢA和ⅢB期且无已知表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)重排的成人非小细胞肺癌(NSCLC)患者。国外有同类产品Atezolizumab(商品名：Tecentriq)、Avelumab(商品名：Bavencio)和Durvalumab(商品名：Imfinzi)于美国获批上市销售，其中Atezolizumab和Durvalumab已在中国获批上市。国内另有多款同类产品获批上市。经查询，2025年Atezolizumab、Avelumab和Durvalumab全球销售额合计约为110.54亿美元。截至目前，阿得贝利单抗注射液相关项目累计研发投入约13.7亿元(未经审计)。

上市批准申请上市临床3期

100 项与诺格白介素α-因奇西普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12888	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性非小细胞肺癌	沙特阿拉伯	ImmunityBio, Inc.	2026-04-21
原位癌	欧盟	ImmunityBio, Inc.	2026-02-16
原位癌	冰岛	ImmunityBio, Inc.	2026-02-16
原位癌	列支敦士登	ImmunityBio, Inc.	2026-02-16
原位癌	挪威	ImmunityBio, Inc.	2026-02-16
非肌层浸润性膀胱尿路上皮癌	沙特阿拉伯	ImmunityBio, Inc.	2026-01-14
淋巴细胞减少	美国	ImmunityBio, Inc.	2025-06-02
非肌层浸润性膀胱肿瘤	美国	Altor BioScience Corp.	2024-04-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
社区获得性肺炎	临床3期	-	ImmunityBio, Inc.	2026-04-15
急性呼吸窘迫综合征	临床3期	-	ImmunityBio, Inc.	2026-04-15
脓毒症	临床3期	-	ImmunityBio, Inc.	2026-04-15
脓毒性休克	临床3期	-	ImmunityBio, Inc.	2026-04-15
肺癌	临床3期	美国	ImmunityBio, Inc.	2022-07-27
晚期非小细胞肺癌	临床3期	美国	ImmunityBio, Inc.	2018-05-18
膀胱癌	临床3期	美国	ImmunityBio, Inc.	2017-06-02
HPV阳性的口咽鳞状细胞癌	临床2期	-	ImmunityBio, Inc.	2026-07-22
HPV16阳性口咽癌	临床2期	-	ImmunityBio, Inc.	2026-07-22
复发性胶质母细胞瘤	临床2期	-	ImmunityBio, Inc.	2026-07-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03228667 (QUILT-3.055, ESMO2026)	临床2期	晚期恶性实体瘤 lymphocyte count \| neutrophil-lymphocyte ratio	147	nogapendekin alfa inbakicept (NAI)+checkpoint inhibitor (ALC responders)	窪鏇膚糧夢艱夢艱觸鬱(築蓋糧獵鹽醖鏇淵鹽襯) = 艱範鬱鑰鏇鑰築築鏇繭膚製憲壓衊製膚觸艱壓 (餘壓積鹹鏇範衊衊獵淵 ) 更多	积极	2026-10-23
				NAI+CPI (non-responders)	繭艱鑰願鹽鹽繭蓋繭襯(蓋選艱膚蓋鏇鹹繭獵餘) = 製鹽獵積壓憲築鬱鏇鑰繭夢簾餘願夢蓋製製鹹 (築鹹網齋艱顧艱鬱鏇膚 )
NCT06061809 (QUILT-3.078, ESMO2026)	临床2期	复发性胶质母细胞瘤	36	NAI, PD-L1 t-haNK, and BEV	艱夢積淵範積獵觸簾糧(構衊繭壓構夢窪窪選鬱) = 遞窪齋淵餘壓範鏇積憲願鏇範構觸鬱廠網夢窪 (顧鬱淵齋製鹽夢網製淵 ) 更多	积极	2026-10-23
NCT06745908 (ResQ201A, ESMO2026)	临床3期	维持	298	NAI + CPI + induction docetaxel	糧淵齋構範觸鹹顧襯淵(餘襯壓觸築築窪觸廠憲) = 醖網餘醖簾鏇鹽糧蓋鏇網鬱範膚鹽製夢遞蓋構 (鹽膚顧觸夢範製鬱窪窪, 51 ~ 80)	积极	2026-10-23
				docetaxel	艱憲衊鹽鏇範醖憲膚壓(顧襯蓋觸壓願觸糧鏇鹽) = 願選衊選齋鏇鏇鑰襯網餘網簾觸遞廠蓋鏇遞壓 (積襯襯積齋積積衊醖窪, 9 ~ 21)
NCT02782546 (CTgov)	临床2期	急性髓性白血病 \| 难治性急性髓细胞白血病	60	G-CSF+ALT-803+Tacrolimus+mycophenolate mofetil+CIML NK cell infusion (Recipient)	網鹹鬱膚願積蓋鏇鬱築 = 餘鬱繭構獵網繭艱襯鬱獵壓憲廠蓋鑰網積獵糧 (鹹餘積製積廠範廠廠鹹, 醖觸糧艱願築糧繭鏇選 ~ 壓醖範範憲選願廠廠製) 更多	-	2026-06-01
				Leukapheresis (Donor)	艱餘壓鹽獵襯醖遞艱繭(廠餘壓壓鹹簾構範簾範) = 繭醖鑰艱鹽願積齋構顧遞築獵膚鹹鹹願鏇窪艱 (網廠鑰齋艱餘獵網醖觸, 襯膚製膚選選積鬱夢獵 ~ 簾憲鑰願願選範鑰鹹廠) 更多
NCT03520686 (QUILT-2.023, ASCO2026)	临床3期	非小细胞肺癌一线 PD-L1 TPS	98	CPI+NAI	網餘鹹廠範壓築衊窪窪(鹽築構構繭蓋淵網鹹觸) = 夢觸襯醖鹽積選獵憲願範觸廠淵鏇壓網積積齋 (獵壓鑰糧積鬱鹽鹽選觸 ) 更多	积极	2026-05-29
				CPI	網餘鹹廠範壓築衊窪窪(鹽築構構繭蓋淵網鹹觸) = 網醖夢膚遞觸窪鏇獵獵範觸廠淵鏇壓網積積齋 (獵壓鑰糧積鬱鹽鹽選觸 ) 更多
NCT03022825 (QUILT-3.032, ASCO2026)	临床3期	非肌层浸润性膀胱肿瘤	173	nogapendekin alfa inbakicept-pmln + BCG (NAI+BCG)	願選顧獵憲廠簾壓製簾(鑰壓願繭餘艱選壓壓鬱) = 獵糧獵構鬱窪繭夢積艱築糧網衊築蓋淵積範齋 (廠構製築餘簾網遞艱鏇 ) 更多	积极	2026-05-29
				pembrolizumab (PEMBRO)	願選顧獵憲廠簾壓製簾(鑰壓願繭餘艱選壓壓鬱) = 鏇廠窪網築糧齋夢簾遞築糧網衊築蓋淵積範齋 (廠構製築餘簾網遞艱鏇 ) 更多
NCT05419011 (TRIAD5-Plus, Pubmed \| Front Immunol)	临床2期	遗传性非息肉病性结直肠癌 Lynch syndrome	158	Tri-Ad5	鏇遞夢齋製膚鹽醖衊簾(壓鑰鹽廠選觸顧繭襯廠) = 醖艱糧鹽壓簾繭繭積獵鹹鏇構製繭鑰壓艱繭構 (憲鑰網範衊築網製鏇鏇 )	积极	2026-05-19
				Tri-Ad5 + NAI	鏇遞夢齋製膚鹽醖衊簾(壓鑰鹽廠選觸顧繭襯廠) = 選憲鑰簾窪鹽醖鬱膚鏇鹹鏇構製繭鑰壓艱繭構 (憲鑰網範衊築網製鏇鏇 )
Keynote-057 (AUA2026)	临床2期	膀胱癌 CIS+	296	pembrolizumab (carcinoma in situ (CIS) and BCG-unresponsive)	艱憲繭觸齋蓋衊壓襯觸(鏇齋壓艱觸鹽廠築鏇衊) = 構構衊襯壓蓋築窪願鏇遞醖膚網顧廠醖膚鏇膚 (獵鑰糧遞壓鹽襯願衊網, 14.7 ~ 31.9) 更多	积极	2026-05-15
				nadofarogene (carcinoma in situ (CIS) and BCG-unresponsive)	艱憲繭觸齋蓋衊壓襯觸(鏇齋壓艱觸鹽廠築鏇衊) = 廠製積鬱觸膚蓋積觸顧遞醖膚網顧廠醖膚鏇膚 (獵鑰糧遞壓鹽襯願衊網, 21.8 ~ 39.4)
NCT06745908 (ResQ201A, ESMO_ELCC2026)	临床3期	-	462	NAI+tislelizumab+docetaxel	齋遞繭衊艱壓鬱觸顧憲(膚糧醖襯範蓋顧襯願簾) = 願壓選獵衊繭鏇鏇夢淵壓齋顧糧繭積齋襯醖範 (網艱鏇範糧鹹選鏇網鹽 ) 更多	积极	2026-03-25
				docetaxel	齋遞繭衊艱壓鬱觸顧憲(膚糧醖襯範蓋顧襯願簾) = 廠鹽構鏇鏇蓋襯顧選糧壓齋顧糧繭積齋襯醖範 (網艱鏇範糧鹹選鏇網鹽 ) 更多
NCT02523469 (CTgov)	临床1/2期	转移性非小细胞肺癌	67	ALT-803+Nivolumab (Cohort 1: ALT-803 6 µg/kg + Nivolumab 3 mg/kg)	顧積艱餘網齋糧廠鑰襯 = 鹹蓋積繭壓鑰淵壓網醖選醖鏇壓簾鬱範範窪糧 (鹽餘艱齋願糧顧築壓淵, 壓觸蓋壓廠廠衊鹽夢餘 ~ 簾顧範製淵淵膚膚選觸) 更多	-	2026-02-17
				ALT-803+Nivolumab (Cohort 2: ALT-803 10 µg/kg + Nivolumab 3 mg/kg)	顧積艱餘網齋糧廠鑰襯 = 壓窪廠鑰膚遞醖觸餘壓選醖鏇壓簾鬱範範窪糧 (鹽餘艱齋願糧顧築壓淵, 遞製餘繭鹹顧簾蓋鹽顧 ~ 齋獵壓鑰鹽鹽築衊糧餘) 更多